Bayer (OTCMKTS:BAYRY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “As part of its strategy to complete the planned acquisition of Monsanto, Bayer inked an agreement to sell selected Crop Science businesses to BASF. With this agreement, the company will actively address the authorities’ possible concerns regarding the planned acquisition of Monsanto and facilitate a successful closing of the transaction by early 2018. The combined enterprise will be able to bring innovations to the market faster and provide its customers with better solutions. However, the company is facing generic competition for many of its products including the Yaz franchise (oral contraceptives). The generics of key drugs will negatively impact revenues. Yet, Bayer’s shares have outperformed the industry year to date. Estimates have increased ahead of the Q4 earnings results. The company has a positive record of earnings surprises in recent quarters.”

A number of other brokerages have also recently issued reports on BAYRY. ValuEngine upgraded shares of Bayer from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. BNP Paribas upgraded shares of Bayer from a “neutral” rating to an “outperform” rating in a research note on Monday, September 25th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Bayer presently has an average rating of “Hold” and a consensus target price of $36.00.

Shares of Bayer (OTCMKTS:BAYRY) traded up $0.02 during trading on Thursday, reaching $31.82. 440,616 shares of the company were exchanged, compared to its average volume of 426,639. The company has a market cap of $105,070.00, a PE ratio of 27.91, a price-to-earnings-growth ratio of 1.95 and a beta of 1.14. Bayer has a 52 week low of $26.98 and a 52 week high of $35.41. The company has a current ratio of 1.51, a quick ratio of 1.01 and a debt-to-equity ratio of 0.67.

Bayer (OTCMKTS:BAYRY) last announced its quarterly earnings results on Thursday, October 26th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.29 by $0.14. Bayer had a net margin of 10.88% and a return on equity of 18.53%. research analysts anticipate that Bayer will post 2.27 earnings per share for the current fiscal year.

WARNING: “Bayer (BAYRY) Cut to Hold at Zacks Investment Research” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/18/bayer-bayry-cut-to-hold-at-zacks-investment-research.html.

About Bayer

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.

Get a free copy of the Zacks research report on Bayer (BAYRY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.